Rosetta Genomics (ROSG +9.7%) spikes as New York grants final approval for its miRview lung...

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Rosetta Genomics (ROSG +9.7%) spikes as New York grants final approval for its miRview lung assay that can accurately differentiate between the four main subtypes of lung cancer using small amounts of tumor cells. With this approval, ROSG can continue to offer miRviev in all 50 U.S. states; NY is the only state that requires an independent regulatory review process for lab-developed tests.